Jun 11, 2020
Lupin Pharmaceuticals and PlushCare Expand Access to Bacterial Vaginosis (BV) Treatment to Help Meet Patient Needs During COVID-19 Pandemic
Oct 28, 2019
FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
Oct 21, 2019
Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg
Aug 12, 2019
binx health Receives FDA 510(k) Clearance For Rapid Point Of Care Platform For Women's Health
May 06, 2019
Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.
Dec 10, 2018
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years
Oct 16, 2018
FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
Sep 06, 2018
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Jul 03, 2018
Pelvic Exams Do Not Help Diagnose STDs In Adolescent Girls, Study Says
May 07, 2018
Medicines360, WCG, and Population Services International Announce Launch of AVIBELA(TM) Hormonal Intrauterine System in Madagascar
Apr 30, 2018
Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study
Apr 26, 2018
Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018
Apr 09, 2018
New Survey: False Beliefs about Sexual Risk, Poor Physician-Patient Communication May Impede STD Screening in Young Women